Annals of surgery · 2024
Biochemical, Radiographic, or Pathologic Response to Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: Which Is Best?
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ahmad Mohammed Usman, Javadi Christopher S, Chang Julia D, Forgó Erna, Delitto Daniel J, Dua Monica M, Fisher George A, Heestand Gregory M, Chang Daniel T, Pollom Erqi, Vitzthum Lucas K, Kirane Amanda, Lee Byrne, Visser Brendan C, Norton Jeffrey A, Poultsides George A
Аннотация
OBJECTIVE: To examine the optimal method of assessing response to neoadjuvant therapy (NAT) in patients with operable pancreatic ductal adenocarcinoma (PDAC).
BACKGROUND: PDAC response to NAT is measured with biochemical, radiographic, and pathologic parameters, which can often be discordant with each other.
METHODS: Patients with PDAC undergoing resection after NAT at a single institution were retrospectively analyzed. Tumor response was assessed using pre/post-NAT carbohydrate antigen 19-9 (CA19-9) levels, radiographic decrease in tumor diameter, and pathologic tumor regression grade. The association of these factors with overall survival (OS) was compared using Kaplan-Meier, Cox regression, and recursive partitioning analysis, a machine learning technique that can validate prediction models for complex hierarchical relationships.
RESULTS: From 2011 to 2022, 225 patients underwent pancreatectomy after NAT (Folfirinox, 70%; gemcitabine + nab-paclitaxel, 19%; radiation, 18%). Almost half required vascular resection (portal vein, 39%; celiac axis 8%). Improved OS was observed after CA19-9 decrease >50% (32 vs 24 months, P = 0.0028), but not after major pathologic (tumor regression grade: 0-1, P = 0.067) or radiographic response (tumor diameter decrease >30%, P = 0.89). However, recursive partitioning analysis identified that the coexistence of biochemical and major pathologic response (achieved in 9% of patients) was associated with the longest OS (40 months, P = 0.0086). This optimal dual response combination was more commonly observed after neoadjuvant radiotherapy was used after systemic chemotherapy (45% vs 11%, P < 0.001).
CONCLUSIONS: CA19-9 response to NAT alone is not enough to identify long-term postresection PDAC survivors. The coexistence of CA19-9 and major pathologic response was predictive of the most optimal survival outcome.
BACKGROUND: PDAC response to NAT is measured with biochemical, radiographic, and pathologic parameters, which can often be discordant with each other.
METHODS: Patients with PDAC undergoing resection after NAT at a single institution were retrospectively analyzed. Tumor response was assessed using pre/post-NAT carbohydrate antigen 19-9 (CA19-9) levels, radiographic decrease in tumor diameter, and pathologic tumor regression grade. The association of these factors with overall survival (OS) was compared using Kaplan-Meier, Cox regression, and recursive partitioning analysis, a machine learning technique that can validate prediction models for complex hierarchical relationships.
RESULTS: From 2011 to 2022, 225 patients underwent pancreatectomy after NAT (Folfirinox, 70%; gemcitabine + nab-paclitaxel, 19%; radiation, 18%). Almost half required vascular resection (portal vein, 39%; celiac axis 8%). Improved OS was observed after CA19-9 decrease >50% (32 vs 24 months, P = 0.0028), but not after major pathologic (tumor regression grade: 0-1, P = 0.067) or radiographic response (tumor diameter decrease >30%, P = 0.89). However, recursive partitioning analysis identified that the coexistence of biochemical and major pathologic response (achieved in 9% of patients) was associated with the longest OS (40 months, P = 0.0086). This optimal dual response combination was more commonly observed after neoadjuvant radiotherapy was used after systemic chemotherapy (45% vs 11%, P < 0.001).
CONCLUSIONS: CA19-9 response to NAT alone is not enough to identify long-term postresection PDAC survivors. The coexistence of CA19-9 and major pathologic response was predictive of the most optimal survival outcome.